Abstract
Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and “biomarker-driven” treatments. However, the impact of this approach on the everyday clinic has yet to be determined. Most precision oncology reports are based on developed countries and usually involve metastatic, hard-to-treat or incurable cancer patients. Moreover, in many cases race and ethnicity in these studies is commonly unreported and real-world evidence in this topic is scarce. Herein, we report data from a total of 202 Chilean advanced stage refractory cancer patients. Retrospectively, we collected patient data from NGS tests and IHC in order to determine the proportion of patients that would benefit from targeted treatments. Overall >20 tumor types were included in our cohort and 37% of patients (n = 74) displayed potentially actionable alterations, including on-label, off-label and immune checkpoint inhibitor recommendations. Our findings were in-line with previous reports such as the cancer genome atlas (TCGA). To our knowledge, this is the first report of its kind in Latin America delivering real-world evidence to estimate the percentage of refractory tumor patients that might benefit from precision oncology. Although this approach is still in its infancy in Chile, we strongly encourage the implementation of mutational tumor boards in our country in order to provide more therapeutic options for advanced stage refractory patients.
Highlights
IntroductionThe ultimate goal of precision oncology is to deliver the right cancer treatment to the right patient in a timely manner
Introduction conditions of the Creative CommonsThe ultimate goal of precision oncology is to deliver the right cancer treatment to the right patient in a timely manner
Patients diagnosed with advanced or metastatic solid cancer and who underwent tumor genomic profiling were eligible for inclusion in this study
Summary
The ultimate goal of precision oncology is to deliver the right cancer treatment to the right patient in a timely manner. The combined use of NGS gene-panels that expand the number of genes that can be simultaneously analyzed, along with immunohistochemistry (IHC)-based techniques, increases the possibility of finding a matching targeted therapy. Phase II clinical trials demonstrate the effectiveness of targeted therapies. These studies are commonly focused on a small subset of cancer patients that harbor specific alterations and/or clinical characteristics. Precision oncology reports on real world data are somewhat scarce. These reports are mainly based on North American, European and Asian countries.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
